
Photo taken from EMD Serono/LinkedIn
Nov 5, 2023, 18:42
A strategic collaboration with Jiangsu Hengrui Pharmaceuticals and EMD Serono
EMD Serono posted on LinkedIn.
“News: Today we entered a strategic collaboration with Jiangsu Hengrui Pharmaceuticals. This agreement aims to strengthen our robust internal oncology pipeline in DNA damage response (DDR) inhibition and antibody-drug conjugates (ADC) to deliver on our ambition to advance therapeutic options for patients with difficult-to-treat cancers. Learn more here.”
Source: EMD Serono/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 26, 2025, 15:14
Mar 26, 2025, 15:07
Mar 26, 2025, 14:53
Mar 26, 2025, 14:43
Mar 26, 2025, 14:26
Mar 26, 2025, 14:11
Mar 26, 2025, 14:01